Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary… Read more
Recce Pharmaceuticals Ltd (RECEF) - Net Assets
Latest net assets as of June 2025: $-3.05 Million USD
Based on the latest financial reports, Recce Pharmaceuticals Ltd (RECEF) has net assets worth $-3.05 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.41 Million) and total liabilities ($15.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.05 Million |
| % of Total Assets | -24.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | -114.89% |
| 10-Year Change | -186.86% |
| Growth Volatility | 305.09 |
Recce Pharmaceuticals Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Recce Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Recce Pharmaceuticals Ltd (2013–2025)
The table below shows the annual net assets of Recce Pharmaceuticals Ltd from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-3.05 Million | +67.95% |
| 2024-06-30 | $-9.52 Million | -267.88% |
| 2023-06-30 | $-2.59 Million | -125.73% |
| 2022-06-30 | $10.06 Million | -50.93% |
| 2021-06-30 | $20.50 Million | +786.62% |
| 2020-06-30 | $2.31 Million | +670.16% |
| 2019-06-30 | $-405.60K | -158.37% |
| 2018-06-30 | $694.91K | +17.75% |
| 2017-06-30 | $590.14K | -83.21% |
| 2016-06-30 | $3.51 Million | -25.46% |
| 2015-06-30 | $4.71 Million | +8557.93% |
| 2014-06-30 | $-55.74K | +25.62% |
| 2013-06-30 | $-74.93K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Recce Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9091436700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $81.50 Million | % |
| Other Comprehensive Income | $6.95 Million | % |
| Total Equity | $-3.05 Million | 100.00% |
Recce Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kuang Hong Arts Management
TWO:6596
|
$120.62 Million |
|
GOLFZON Co. Ltd
KQ:215000
|
$120.67 Million |
|
Empresas Lipigas S.A.
SN:LIPIGAS
|
$120.71 Million |
|
Tigo Energy Inc.
NASDAQ:TYGO
|
$120.71 Million |
|
APAC Resources Limited
F:FZV1
|
$120.60 Million |
|
Globaltek Fabrication Co Ltd
TW:4566
|
$120.53 Million |
|
Foraco International SA
PINK:FRACF
|
$120.53 Million |
|
Desiccant Technology Corporation
TW:5292
|
$120.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Recce Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -9,523,768 to -3,052,004, a change of 6,471,764.
- Net loss of 21,428,089 reduced equity.
- New share issuances of 28,350,213 increased equity.
- Other comprehensive income increased equity by 1,236,897.
- Other factors decreased equity by 1,687,257.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.43 Million | -702.1% |
| Share Issuances | $28.35 Million | +928.9% |
| Other Comprehensive Income | $1.24 Million | +40.53% |
| Other Changes | $-1.69 Million | -55.28% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Recce Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | $0.00 | $0.60 | x |
| 2014-06-30 | $0.00 | $0.60 | x |
| 2015-06-30 | $0.14 | $0.60 | x |
| 2016-06-30 | $0.06 | $0.60 | x |
| 2017-06-30 | $0.01 | $0.60 | x |
| 2018-06-30 | $0.01 | $0.60 | x |
| 2019-06-30 | $0.00 | $0.60 | x |
| 2020-06-30 | $0.02 | $0.60 | x |
| 2021-06-30 | $0.13 | $0.60 | x |
| 2022-06-30 | $0.06 | $0.60 | x |
| 2023-06-30 | $-0.01 | $0.60 | x |
| 2024-06-30 | $-0.05 | $0.60 | x |
| 2025-06-30 | $-0.01 | $0.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Recce Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -285.37%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-97.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -75571.06% | 0.00x | 0.00x | $-284.94K |
| 2014 | 0.00% | -280.43% | 0.66x | 0.00x | $-266.80K |
| 2015 | -9.55% | -395.39% | 0.02x | 1.06x | $-921.58K |
| 2016 | -137.75% | -2734.36% | 0.05x | 1.06x | $-5.19 Million |
| 2017 | -512.67% | -2172.01% | 0.10x | 2.48x | $-3.08 Million |
| 2018 | -240.93% | -129.94% | 1.13x | 1.65x | $-1.74 Million |
| 2019 | 0.00% | -410.40% | 0.74x | 0.00x | $-2.75 Million |
| 2020 | -186.66% | -384.83% | 0.35x | 1.40x | $-4.55 Million |
| 2021 | -65.91% | -825.30% | 0.08x | 1.06x | $-15.56 Million |
| 2022 | -109.19% | -356.12% | 0.24x | 1.25x | $-11.99 Million |
| 2023 | 0.00% | -299.58% | 1.71x | 0.00x | $-12.82 Million |
| 2024 | 0.00% | -257.84% | 1.08x | 0.00x | $-16.71 Million |
| 2025 | 0.00% | -285.37% | 0.60x | 0.00x | $-21.12 Million |
Industry Comparison
This section compares Recce Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Recce Pharmaceuticals Ltd (RECEF) | $-3.05 Million | 0.00% | N/A | $120.60 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |